Pharmacotherapy for mood, anxiety, and cognitive disorders
Author(s)
Bibliographic Information
Pharmacotherapy for mood, anxiety, and cognitive disorders
American Psychiatric Press, 2000
Available at 4 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Our limited knowledge of the pathophysiology underlying mood disorders contrasts sharply with the efficacy of the treatment modalities developed over the past decades. There has been an explosion of new antidepressant and anxiolytic medications, as well as mood stabilizers and compounds that aim to improve cognition. Although treatment success is still not optimal, pharmacotherapy for mood disorders and cognitive disorders is effective and is improving.
Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders takes a critical look at the medications available for treating mood, anxiety and cognitive disorders; their relevance to pathobiology and underlying mechanisms; and their limitations. Its 90 distinguished contributors, many of them pioneers in the development of treatment modalities, provide background and rationale in understanding the underlying mechanisms of frontline treatments for these disorders. This book reviews
* Effective new alternatives in mood stabilizers and antidepressant interventions
* Advances in the study of the pathobiology of anxiety disorders as well as available treatment choices, including anxiolytic medications
* Several treatment approaches to dementia and other age-related cognitive impairments
* Gender differences in the treatment of depression and anxiety and the different responses to pharmacotherapy
* New treatments for social phobia and pharmacological strategies for cognitive disorders
Providing both a broad overview and detailed reviews of pharmacotherapy, this resource is essential reading for any practitioner who wants to understand the rationale and background for the drugs he or she prescribes and to assess medications that are currently under development. It is a great reference and ancillary text for students and residents during their clinical years.
Table of Contents
Contributors
Section I: Overviews
Chapter 1. Pharmacotherapy for mood, anxiety, and cognitive disorders: An overview
Chapter 2. Current theories on the pathophysiology of mood disorders
Chapter 3. Pharmacological validity of diagnostic separation
Chapter 4. Signal amplification in psychiatric diagnosis: Therapeutic implications
Chapter 5. Gender differences in treatment of depression and anxiety
Section II: Mood Stabilizers
Chapter 6. Carbamazepine and nimodipine in refractory bipolar illness: Efficacy and mechanisms
Chapter 7. Mechanisms of action of lithium in bipolar illness
Chapter 8. Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium
Chapter 9. Therapeutic potential of inositol treatment in depression, panic, dementia, and lithium side effects
Chapter 10. Electroconvulsive therapy: Current practice and future directions
Chapter 11. Antidepressant and mood stabilization effects potential of transcranial magnetic stimulation
Section III: Antidepressants
Chapter 12. Changing targets of antidepressant therapy: Serotonin and beyond
Chapter 13. New emerging serotonergic antidepressants
Chapter 14. Dopamine receptors and antidepressant development
Chapter 15. Noradrenergic and other new antidepressants
Chapter 16. Sleep in depression and the effects of antidepressants on sleep
Chapter 17. Hormonal interventions as antidepressants or adjunct therapy: Treatment implications
Chapter 18. Mechanisms and management of treatment-resistant depression
Chapter 19. Treatment of psychotic depression
Chapter 20. Antidepressant maintenance medications
Section IV: Anxiolytics
Chapter 21. Overview of new anxiolytics
Chapter 22. Interactions between physiological, hormonal, and environmental determinants: The anxiety model
Chapter 23. Serotonin-specific anxiolytics: Now and in the future
Chapter 24. Serotonergic treatments for panic disorder
Chapter 25. New treatments for social phobia
Chapter 26. Why a peptide as an anxiolytic?
Chapter 27. Cholecystokinin antagonists in panic and anxiety disorders
Chapter 28. Neurosteroids
Chapter 29. Nonbenzodiazepine anxiolytics acting on the GABA receptor
Chapter 30. Treatment of obsessive-compulsive disorder: From theory to practice
Chapter 31. New approaches to treatment-refractory obsessive-compulsive disorder
Section V: Cognition and Dementia
Chapter 32. Pharmacological strategies for cognitive disorders: An overview
Chapter 33. Cholinergic approaches to cognition and dementia
Chapter 34. Serotonin mechanisms and cognition
Chapter 35. Nicotinic cholinergic approaches to cognitive enhancement in the dementias
References
Index
by "Nielsen BookData"